Efficacy and safety of front-line treatments for advanced Hodgkin lymphoma: a systematic literature review
| Autor: | Ajibade O Ashaye, Jatin Gupta, Kim Price, Harry Miao, Mehul Dalal, Athanasios Zomas |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
BEACOPP
Oncology Diagnostic Imaging Vincristine medicine.medical_specialty medicine.medical_treatment Dacarbazine Bleomycin 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols polycyclic compounds Medicine Humans Brentuximab vedotin Etoposide Neoplasm Staging Randomized Controlled Trials as Topic Clinical Trials as Topic business.industry Age Factors Disease Management Hematology respiratory system Prognosis Hodgkin Disease respiratory tract diseases Vinblastine carbohydrates (lipids) Treatment Outcome ABVD chemistry 030220 oncology & carcinogenesis business Publication Bias 030215 immunology medicine.drug |
| Zdroj: | Expert review of hematology. 13(8) |
| ISSN: | 1747-4094 |
| Popis: | To assess evidence on the safety and efficacy of ABVD (doxorubicin [Adriamycin®], bleomycin, vinblastine, and dacarbazine), BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone), and A+AVD (brentuximab vedotin, with doxorubicin, vinblastine, and dacarbazine) for advanced-stage Hodgkin lymphoma (HL). A systematic literature review (SLR) was conducted on 29 July 2016 (updated 26 July 2018) to identify randomized controlled trials (RCTs) and non-RCTs assessing the treatment of newly-diagnosed advanced-stage HL with ABVD and BEACOPP (and their variants), and A+AVD. The SLR identified 62 RCTs and 42 non-RCTs. Five-year overall survival rates for ABVD and BEACOPP were 60–97% and 84–99%, and 5-year progression-free survival rates were 58–81% and 83–96%, respectively. Both regimens were associated with tolerability issues and side effects. Discontinuation or dose reduction of bleomycin resulted in fewer adverse events, without significantly affecting efficacy. A head-to-head trial demonstrated improved efficacy for A+AVD vs ABVD, with an acceptable tolerability profile. No data from head-to-head trials comparing A+AVD with BEACOPP were available, and an indirect treatment comparison was not feasible. New therapies, such as A+AVD, maintain the efficacy observed with current treatments, and may provide a more tolerable treatment option for patients with advanced-stage HL. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|